Doxorubicin-induced cardiac injury remains a major clinical challenge in oncology. The drug generates reactive oxygen species, disrupts mitochondrial function and triggers programmed cell death in cardiomyocytes, the contractile cells of the heart, eventually leading to arrhythmias and heart failure that can appear within days of a high dose or years after treatment ends. Until now, the only widely accepted preventive strategy has been dexrazoxane, an iron-chelating agent that offers partial protection but does not eliminate the risk. Because the cardiomyocyte has been treated as the primary victim and the primary subject of investigation, the role of the cardiac fibroblast in chemotherapy cardiotoxicity has remained, in the authors’ words, incompletely defined. The new study set out to test whether GNL3, a GTP-binding protein better known for its roles in tumor biology and cell proliferation, might matter in this setting.

The experimental design was unusually rigorous for a mechanistic cardiology study. The team created two lines of genetically engineered mice: one in which GNL3 was specifically deleted from cardiac fibroblasts, and another in which the protein was specifically overproduced in those same cells. They then subjected both lines to a single intraperitoneal injection of doxorubicin at 15 milligrams per kilogram, a standard acute injury model that reproduces the kind of cardiac stress seen clinically after high-dose chemotherapy. Using echocardiography to measure heart function in living animals, along with western blotting, quantitative PCR, immunofluorescence, co-immunoprecipitation and chromatin immunoprecipitation to dissect molecular events, the researchers tracked both the injury and the signaling pathways underlying it.

The results were striking. GNL3 expression rose sharply in the hearts of doxorubicin-treated mice, and the increase was concentrated in the fibroblast fraction of the tissue. When the researchers deleted GNL3 from cardiac fibroblasts, the mice fared markedly better: myocardial injury was reduced, oxidative stress declined, cardiomyocyte apoptosis decreased, and systolic function — the heart’s ability to pump blood — was better preserved. Conversely, mice engineered to overexpress GNL3 in their fibroblasts suffered worse outcomes across all of these measures, and their survival was reduced after doxorubicin exposure. In a critical control experiment, deleting GNL3 from cardiomyocytes themselves produced no obvious protective effect, a result that argues strongly against the idea that the protein matters mainly inside the muscle cells and instead points the finger squarely at the fibroblast.

To understand how a protein made in fibroblasts could damage neighboring cardiomyocytes, the team turned to conditioned medium assays, a technique in which cardiomyocytes are grown in a bath of liquid previously occupied by doxorubicin-treated fibroblasts. When the culture medium came from fibroblasts with high GNL3 levels, the exposed cardiomyocytes showed more injury-associated damage; when GNL3 was removed from the fibroblasts, the medium was less harmful. This established that GNL3 acts, at least in part, through secreted factors — a paracrine mechanism in which one cell type changes the chemical environment of another. The central suspect in that chemical conversation turned out to be Fas ligand, or FasL, a death receptor ligand famous in immunology for its role in instructing cells to undergo apoptosis.

The molecular trail leading to FasL ran through a well-characterized signaling pathway known as calcineurin/NFATc1, or CaN/NFATc1. Calcineurin is a calcium-dependent phosphatase, and NFATc1 is a transcription factor that it activates; when active, NFATc1 moves into the nucleus and binds to promoter regions of target genes to switch them on. Using chromatin immunoprecipitation, the researchers demonstrated that GNL3 was functionally linked to this axis and that increased NFATc1 occupancy at the Fasl promoter occurred in cardiac fibroblasts — in other words, GNL3 upregulation drives the transcription factor to dock onto the gene for FasL and crank up its production. Fibroblasts loaded with GNL3 consequently secreted more FasL, which then traveled to neighboring cardiomyocytes and pushed them toward apoptosis, oxidative stress and functional decline.

This fibroblast-to-cardiomyocyte death signal is what the authors describe as FasL-linked crosstalk, and it reframes the architecture of chemotherapy cardiotoxicity. Rather than a single cell type succumbing to a toxic drug, the heart’s response to doxorubicin emerges as a coordinated collapse involving multiple cell populations: the drug induces GNL3 in fibroblasts, GNL3 activates calcineurin and NFATc1, NFATc1 amplifies Fasl transcription, and secreted FasL delivers a lethal message to the contractile cells. It is a chain reaction in which the supporting cast of the heart becomes a transmitter of damage, and interrupting any link in the chain — as the knockout mice demonstrated — materially protects the organ.

The clinical implications are immediate and tantalizing. If the same pathway operates in human patients, GNL3 or its downstream product FasL could serve as biomarkers for identifying oncology patients at elevated risk of anthracycline cardiotoxicity before symptoms appear, allowing oncologists and cardiologists to tailor dosing, monitoring and cardioprotective therapy. More ambitiously, the pathway itself becomes a drug target. Inhibiting the CaN/NFATc1 axis in cardiac fibroblasts, blocking FasL signaling, or even targeting GNL3 directly could, in principle, shield the heart without compromising doxorubicin’s ability to kill tumor cells — a long-sought goal, since the very mechanism that makes anthracyclines lethal to cancer cells also makes them dangerous to cardiac tissue. The authors are careful to frame these findings as nominating CF-derived GNL3 as a candidate pathway for further investigation rather than as an established therapeutic target, and the work was conducted in mice, so translation to patients will require additional validation.

The study also carries a broader scientific lesson about where to look for answers in cardiovascular medicine. Cardiac fibroblasts were long dismissed as passive scaffolding, but research over the past two decades has progressively revealed them as active participants in nearly every form of heart disease, from fibrosis after myocardial infarction to inflammation in myocarditis. This study extends that re-evaluation into the realm of acute drug toxicity, showing that a stromal cell can dictate whether a chemotherapeutic challenge becomes a survivable insult or a catastrophic one. It also highlights GNL3 itself as a protein whose portfolio is expanding: previously studied mainly in nucleolar biology and cancer, it now appears to function as a stress-responsive regulator in the heart’s supporting cells, wired into one of the most conserved death-signaling pathways in biology.

For the millions of patients who receive anthracycline chemotherapy each year, the promise of this work lies in the possibility of decoupling cancer treatment from cardiovascular harm. The Wuhan team, led by corresponding author Wanli Jiang, has laid out a complete mechanistic arc — from drug exposure to protein upregulation to transcription factor activation to intercellular death signaling to measurable cardiac dysfunction — and each step of that arc is now a potential point of intervention. The research was supported by the Natural Science Foundation for Young Scientists of Hubei Province and the Guiding Program of Natural Science Foundation of Hubei Province, China, and is available open access. As follow-up studies test whether GNL3 behaves the same way in chronic injury models and in human tissue, one conclusion already stands: the heart’s fibroblasts are not bystanders in chemotherapy cardiotoxicity, and silencing the wrong conversation between cells may cost patients their hearts even when the cancer is cured.

Subject of Research: Fibroblast-derived GNL3 signaling in acute doxorubicin-induced cardiac injury

Article Title: Cardiac fibroblast-derived GNL3 aggravates acute doxorubicin-induced cardiac injury via FasL-linked fibroblast–cardiomyocyte crosstalk

Article References: Lu, X., Yang, J., Zhang, H., Zhang, Z., Xing, X., Wan, S., Lai, W., Zhang, Y., & Jiang, W. (2026). Cardiac fibroblast-derived GNL3 aggravates acute doxorubicin-induced cardiac injury via FasL-linked fibroblast–cardiomyocyte crosstalk. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06450-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06450-4

Keywords: doxorubicin, cardiotoxicity, GNL3, cardiac fibroblasts, FasL, NFATc1, apoptosis, oxidative stress, paracrine signaling, anthracyclines, heart failure, calcineurin